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Abstract
Introduction: When breast cancer patients develop distant metastases, the choice of systemic treatment is usually
based on tissue characteristics of the primary tumor as determined by immunohistochemistry (IHC) and/or molecular
analysis. Several previous studies have shown that the immunophenotype of distant breast cancer metastases may
be different from that of the primary tumor (receptor conversion), leading to inappropriate choice of systemic
treatment. The studies published so far are however small and/or methodologically suboptimal. Therefore, definite
conclusions that may change clinical practice could not yet be drawn. We therefore aimed to study receptor
conversion for estrogen receptor alpha (ERa), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2) in a large group of distant (non-bone) breast cancer metastases by re-staining all primary tumors
and metastases with current optimal immunohistochemical and in situ hybridization methods on full sections.
Methods: A total of 233 distant breast cancer metastases from different sites (76 skin, 63 liver, 43 lung, 44 brain
and 7 gastro-intestinal) were IHC stained for ERa, PR and HER2, and expression was compared to that of the
primary tumor. HER2 in situ hybridization (ISH) was done in cases of IHC conversion or when primary tumors or
metastases showed an IHC 2+ result.
Results: Using a 10% threshold, receptor conversion by IHC for ERa, PR occurred in 10.3%, 30.0% of patients,
respectively. In 10.7% of patients, conversion from ER+ or PR+ to ER-/PR- and in 3.4% from ER-/PR- to ER+ or PR+
was found. Using a 1% threshold, ERa and PR conversion rates were 15.1% and 32.6%. In 12.4% of patients
conversion from ER+ or PR+ to ER-/PR-, and 8.2% from ER-/PR- to ER+ or PR+ occurred. HER2 conversion occurred
in 5.2%. Of the 12 cases that showed HER2 conversion by IHC, 5 showed also conversion by ISH. One further case
showed conversion by ISH, but not by IHC. Conversion was mainly from positive in the primary tumor to negative
in the metastases for ERa and PR, while HER2 conversion occurred equally both ways. PR conversion occurred
significantly more often in liver, brain and gastro-intestinal metastases.
Conclusions: Receptor conversion by immunohistochemistry in (non-bone) distant breast cancer metastases does
occur, is relatively uncommon for ERa and HER2, and is more frequent for PR, especially in brain, liver and gastro-
intestinal metastases.
Introduction
With 1,000,000 new cases causing 375,000 deaths world-
wide per year, breast cancer is the leading cause of
female cancer death worldwide [1]. Early detection, opti-
mal surgery and adjuvant therapy are the key strategies
to improving prognosis. Nevertheless, about one third of
patients will develop distant metastases and eventually
die of the disease. Patients who develop distant metas-
tases usually undergo systemic therapy with chemother-
apy, hormonal therapy and/or human epidermal growth
factor receptor 2 (HER2) targeted therapy. Choice of
therapy is currently personalized on the basis of the
immunophenotype of the primary tumor, since distant
metastases are often not biopsied, partly because of
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limited accessibility of these metastases, but also because
it is not considered necessary for further therapeutic
decision making.
However, previous studies [2-23] have indicated that
receptor status of breast cancer metastases may differ from
the primary tumor, generally denoted “receptor conver-
sion”. The published studies suggest that, compared to the
primary tumors, estrogen receptor (ERa) and progesterone
receptor (PR) are more frequently negative in distant
metastases, whereas HER2 is more often positive. These
observations, if confirmed, have important clinical conse-
quences, since this would mean that a number of patients
are withheld adequate systemic treatment for their metas-
tases. In addition, if immunophenotype conversion would
occur in high frequency, this would make it clinically very
relevant to biopsy (even difficult to access) distant metas-
tases to assess hormone receptor and HER2 status. An
alternative for taking biopsies could be molecular imaging
methods like positron emission tomography (PET) and
single photon emission computed tomography (SPECT)
that are currently being developed to functionally assess
immunophenotype of breast cancer metastases [24-26].
Unfortunately, the previous conversion studies suffer
from several limitations: small size (six studies contain
<30 cases and eight studies ≤62 cases) [2,3,6,7,9,10,
12-15,18-20,22], only one metastatic site studied [9,18],
using a ligand-binding assay [2,3,7,10], which, especially in
the case of metastases, may be biased by low cellularity
and contamination by nonmalignant cells, inclusion of
decalcified bone metastases [2,4,6,8-10,12,16,19,20,22] that
may give rise to false negative immunohistochemistry,
extraction of original immunohistochemistry results from
the pathology report instead of repeating the staining
[3,5,8,10,11,23], and/or use of tissue arrays [21] which may
introduce sampling bias. Therefore, the available data may
not be sufficiently reliable to change current clinical prac-
tice, although several guidelines already advise to rebiopsy
distant metastases when possible [27,28]. Consequently,
for most patients with metastatic breast cancer hormone
receptor and HER2 status in the primary tumor are still
used to guide therapy.
We have now performed a large study analyzing
metastases from different sites, while restaining metas-
tases and primary tumors side-by-side with optimal cur-
rent immunohistochemical methods for ERa, PR and
HER2 on full sections to asses the conversion rate of
ERa, PR and HER2 status in distant metastases com-
pared to the primary breast carcinomas.
Materials and methods
Patients
Two hundred and thirty-three primary breast carcinomas
and corresponding metachronous non-bone distant
metastases from female patients were obtained from the
departments of pathology of the University Medical
Center Utrecht, the Academic Medical Center Amster-
dam, the Radboud University Nijmegen Medical Centre,
the Canisius Wilhelmina Hospital Nijmegen, the Nether-
lands Cancer Institute Amsterdam, the Medical Center
Alkmaar, the Medical Center Zaandam, the University
Medical Center Groningen, the St. Antonius Hospital
Nieuwegein, the Diakonessenhuis Utrecht, the Free Uni-
versity Medical Center Amsterdam, and the Laboratory
for Pathology Dordrecht, all in The Netherlands. Original
diagnoses were made between January 1985 and March
2009, and these cases comprised all the paired cases that
could be retrieved from the participating labs during this
period, minimizing selection bias. All histological speci-
mens had been fixed for 12 to 24 hours in neutral buffered
formaldehyde. The vast majority of primary specimens
were paraffin blocks of breast or lumpectomies, except for
17 cases core biopsies from the primary tumors were used
(no cytology). For 11 cases this information was not avail-
able. The sites of the distant metastases are shown in
Table 1. Use of anonymous or coded left over material for
scientific purposes is part of the standard treatment con-
tract with patients in hospitals in The Netherlands [29].
Ethical approval was not required.
For each case, hematoxylin-eosin stained slides of the
paraffin blocks were reviewed by a single pathologist
(PJvD) to confirm the presence of malignancy in tumor
samples.
Histologic type was assessed according to the World
Health Organization. Histologic grade was assessed
according to the Nottingham modification of the
Bloom-Richardson system, applying standardized mitotic
counts [30]. Clinicopathologic characteristics are shown
in Table 1.
Immunohistochemistry
Immunohistochemical analysis was carried out on 4-μm
sections. We did not use the tissue microarray approach,
to avoid sampling bias due to tumor heterogeneity. All
primary tumors and metastases were restained by the
same person (LCDH) according to the same protocol to
allow optimal pair-wise comparisons. For all stainings,
slides were deparaffinized in xylene and rehydrated in
decreasing ethanol dilutions. Endogenous peroxidase
activity was blocked with H2O2 in phosphate buffered
saline (PBS) followed by antigen retrieval. For ERa and
HER2, antigen retrieval was performed in an autoclave
with the slides placed in an EDTA buffer, pH = 9. For
PR antigen retrieval was performed in citrate buffer,
pH = 6 (20 minutes, 100°C). A cooling off period of 30
minutes preceded the incubation (60 minutes, room
temperature) with the primary antibodies.
Mouse monoclonal antibodies used were: ERa
(M7047, 1:80, DAKO, Glostrup, Denmark), PR (M3569,
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1:50, DAKO) and HER2 (RM-9103-S, 1:100, Neomar-
kers, Lab Vision Corporation, Fremont, California,
USA). For detection of the primary antibodies a poly
HRP anti Mouse/Rabbit/Rat IgG (ready to use; Powervi-
sion, Immunovision Technologies, Brisbane, California,
USA) was used. Between steps, slides were washed with
PBS. Finally, peroxidase activity was developed with dia-
minobenzidin, slides were lightly counter-stained with
hematoxylin, dehydrated in increasing alcohol dilutions
and cover slipped. Appropriate negative and positive
controls were used throughout. We regularly participate
in EQA schemes to monitor our performance with these
routine antibodies.
If HER2 status differed between primary tumor and
metastases, or when either primary tumor or metastasis
were IHC 2+ (see below), silver in situ hybridization
(SISH) analysis [31] was performed with a fully auto-
mated technique (INFORM, Ventana Medical Systems,
Tucson, AZ, USA) according to the manufacturer’s
guidelines.
Scoring of IHC slides was performed by one observer
(PJvD) in random order, blinded to other data in the
paired samples. For ERa and PR, the percentage of posi-
tively stained nuclei was estimated. In primary tumor
samples, the adequacy of staining was checked by also
evaluating the normal breast parenchyma when present.
Samples with 10% or more immunopositive malignant
cells were classified as ERa- or PR positive as usual
[8,11,12]. In order to also comply with the most recent
ASCO guidelines [32], we also used the 1% threshold
that is now widely used in the USA. HER2 expression
was scored using the DAKO scoring system as 0, 1+, 2+
and 3+ according to standardized criteria [33], consider-
ing 3+ cases as positive. SISH results were evaluated by
one observer (MJvdV) according to the manufacturer’s
instructions blinded to other data in the paired samples
and immunohistochemistry results. According to the
ASCO/CAP guidelines [34], tumors with <6 HER2
copies/tumor cell nucleus were scored as HER2 non-
amplified; and tumors with 6 or more HER2 copies/
tumor cell nucleus were scored as HER2 amplified.
Statistical analysis
Percentages of nuclei expressing ERa and PR in primary
tumors and their metastases were compared by paired
t-test (SPSS). The frequency of receptor expression
(positive vs negative) in the primary tumors and distant
metastases was calculated. Percentages of conversion
were calculated for the whole group, and for subgroups
of metastatic sites (10% threshold for ERa and PR only).
As steroid receptor conversion is especially important if
a patient converts from ER+ or PR+ to ER-/PR-, or
from ER-/PR- to ER+ or PR+, we calculated the percen-
tages for these conversions as well. Conversion rates for
the different distant sites (10% threshold for ERa and
PR) were compared by chi-square test.
Results
The percentage of nuclei expressing ERa or PR was
generally lower in the distant metastases than in the pri-
mary tumor (Figure 1), but significance was only
reached for PR (P <0.001). Receptor conversion exceed-
ing the threshold of 10% occurred for ERa in 10.3% and
for PR in 30.0% of the patients (Table 2). Such conver-
sion was mainly from positive to negative: 10.7% of the
patients converted from ER+ or PR+ to ER-/PR-, and
3.4% from ER-/PR- to ER+ or PR+. Receptor conversion
exceeding the threshold of 1% occurred for ERa in
15.1% and for PR in 32.6% of the patients (Table 2),
Table 1 Clinicopathologic characteristics of 233 invasive
breast cancer patients studied for receptor conversion in
distant metastases
Feature Grouping N or value %
Age (years) Mean 53.9
Range 25 to 93
Tumor size (cm) ≤2 73 31.3
> 2 and ≤5 80 34.3
> 5 12 5.2
Not available 68 29.2
Histologic type Invasive ductal cancer 192 82.4
Invasive lobular cancer 20 8.6
Others 20 8.6
Not available 1 0.4
Histologic grade 1 8 3.4
2 61 26.2
3 161 69.1
Not available 3 1.3
MAI (per 2 mm2) Mean 25
Range 0 to 172
≤12 71 30.5
≥13 156 67.0
Not available 6 2.5
Lymph node status Positive 119 51.1
Negative 81 34.8
Not available 33 14.2
Site of distant metastases Brain 44 18.9
Lung 43 18.5
Liver 63 27.0
Skin 76 32.6
Gastro-intestinal 7 3.0
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while 12.4% of the patients converted from ER+ or PR+
to ER-/PR-, and 8.2% from ER-/PR- to ER+ or PR+.
Receptor conversion for ERa and PR (10% threshold)
seemed to occur especially in liver (ERa 12.7%, PR
41.2%) and brain metastases (ERa 13.7%, PR 36.3%)
(Table 3). For PR, conversion was significantly more
often seen for brain, liver and gastro-intestinal metas-
tases (P = 0.04).
For HER2, receptor conversion by IHC occurred in
5.2% of patients, about half of them from negative to
positive and the other half from positive to negative
(Table 2). Receptor conversion for HER2 seemed to
occur especially, although not significantly, in liver
metastases (9.5%) (Table 3). Of the 12 cases that showed
HER2 conversion by IHC, 5 showed also conversion by
SISH. One further case showed conversion by ISH, but
not by IHC (Table 4).
Examples of conversion of ERa, PR and HER2 from
primary breast cancers to distant metastases are shown
in Figure 2.
Discussion
Previous studies have shown that distant breast cancer
metastases may show receptor conversion, potentially
leading to inappropriate choices of systemic treatment
in these patients. These previous studies however
Figure 1 Immunophenotype for ERa (a), PR (b) and HER2 (c) in 233 primary breast tumors and their corresponding metastases.
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suffered from several limitations not allowing the
researchers to draw definite conclusions that may
change clinical practice. We therefore set out to reevalu-
ate receptor conversion in a large group of non-bone
distant breast cancer metastases using optimal metho-
dology. Receptor conversion by IHC for ERa, PR and
HER2 occurred in 10.3%, 30.0% and 5.2% of patients,
respectively, using the traditional 10% threshold. When
using the new 1% ERa and PR threshold according to
the ASCO guidelines, conversion rates were even higher
at 15.1% and 32.6%.
Previous studies (all using the 10% threshold when
indicated) reported ERa receptor conversion rates from
12% to 54%, clearly higher than in the present study. The
explanation for this finding may be that previous ERa
studies did not restain both the primary and metastatic
lesions [3,5,8,10,11], used ligand-binding assays [2,3,7,10]
(where the result is influenced by differences in the per-
centage of non-tumor cells in the samples), or included
bone metastases that may suffer from false negative IHC
results due to decalcification [2,4,6,8-10,12]. In addition,
with 233 cases our series is much larger than most
previous ERa studies. Only two previous studies report
on comparable numbers of cases (200 and 211, respec-
tively), but in these studies the original immunohisto-
chemistry results from the pathology report were used
instead of renewed stainings. Previous studies (all using
the 10% threshold when indicated) reported PR conver-
sion rates from 28% to 61%, again higher than in the pre-
sent study. The explanation for this may be similar to
what has been mentioned above: previous studies did not
restain both the primary and metastatic lesions
[5,8,10,11], used ligand-binding assays [2,7,10], or
included bone metastases [2,6,8-10,12]. Further, our ser-
ies is much larger with 233 compared to most previous
PR studies with 9 to 59 cases. There were two previous
studies with respectively 173 and 211 cases, but these
used the original immunohistochemistry results from the
pathology report instead of renewed stainings.
Conversion for ERa and PR was mainly from positive
in the primary tumor to negative in the metastases as
has been described before [2,4,6,8,10-12]. This finding
may well be explained by clonal selection of less differ-
entiated receptor negative cells during the metastatic
process, for example, elicited by adjuvant hormonal
treatment [12,35,36]. However, in a few cases conversion
from negative in the primary tumor to positive in the
metastases occurred. This phenomenon has also been
described before [2,3,8,10,11], but is more difficult to
explain. Although false negative primary tumor results
cannot be fully excluded, we also assessed the adequacy
of staining by analysis of staining of epithelial cells in
the normal ducts and lobules as an internal control. Per-
haps in these cases small receptor positive clones within
the primary tumor preferentially metastasized [37].
Alternatively, this phenomenon could be a result of
genetic drift during tumor progression [38]. Previous
studies reported HER2 immunophenotype conversion
rates from 0% to 58.3%, which is generally higher than
the 5.2% conversion rate we have found in the present
Table 2 HER2 and ERa, PR expression by immunohistochemistry in paired primary breast cancers and their distant
metastases
Distant metastases
Primary tumor Status - + Total
HER2 - 180 (77.2%) 6 (2.6%) 186
+ 6 (2.6%) 41 (17.6%) 47
10% threshold 1% threshold
- + Total - + total
ERa - 79 (33.9%) 7 (3.0%) 86 47 (20.2%) 12 (5.2%) 59
+ 17 (7.3%) 130 (55.8%) 147 23 (9.9%) 151 (64.8%) 147
PR - 92 (39.5%) 12 (5.1%) 104 33 (14.2%) 27 (11.6%) 60
+ 58 (24.9%) 71 (30.5%) 129 49 (21.0%) 124 (53.2%) 173
For ERa and PR, data are shown using both the traditional 10% and new ASCO 1% thresholds.
HER2, human epidermal growth factor receptor 2; ERa, estrogen receptor alpha; PR, progesterone receptor.
Table 3 Receptor conversion for ERa, PR (10% threshold)
and HER2 in distant breast cancer metastases according
to site
% conversion
ERa PR HER2
N N (%) N (%) N(%)
Brain 44 6 (13.7) 16 (36.3)* 1 (2.3)
Lung 43 4 (9.4) 8 (18.6) 2 (4.7)
Liver 63 8 (12.7) 26 (41.2)* 6 (9.5)
Skin 76 5 (6.6) 17 (22.3) 2 (2.6)
Gastro-intestinal 7 1 (14.3) 3 (42.9)* 1 (14.3)
* statistically significantly more often than for lung and skin metastases (P = 0.04,
chi-square test).
ERa, estrogen receptor alpha; PR, progesterone receptor; HER2, human
epidermal growth factor receptor 2.
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study. As mentioned above, previous HER2 studies did
not restain both the primary and metastatic lesions
[10,11,23], used TMAs [21] or included bone metastases
[10,12,16,19,20,22]. Further, our series is much larger
with 233 cases compared to most previous studies with
12 to 211 cases, and in the only larger study (N = 382)
restaining was not performed. By SISH, only half of
these IHC conversions were accompanied by a differ-
ence in HER2 gene amplification status. Therefore, for
only 6 out of the 233 patients (3%) a “true” conversion
on the gene level of HER2 status between primary
tumor and distant metastasis could be demonstrated.
The fact that scoring of HER2 SISH signals is more
straightforward than interpretation of HER2 IHC may
play a role here. Contrary to ERa and PR that preferen-
tially converted from positive in the primary tumors to
negative in the metastases, HER2 receptor conversion
occurred both ways. Although from a tumor progression
model one would expect HER2 conversion to preferen-
tially occur from negative to positive, conversion both
ways has been described before [17,18,20-23]. One
mechanism of conversion from positive to negative may
well be explained by clonal selection of HER2 negative
cells during the metastatic process, for example, elicited
by trastuzumab therapy [39].
When considering the different metastatic sites, recep-
tor conversion seemed to occur mostly in liver and
brain metastases, but only for PR conversion this was
significant. The reason for this observation is unclear,
and these results need to be interpreted with caution.
One limitation to receptor conversion studies is the
lack of internal control cells in samples from most of
the metastatic sites. An exception to this is the liver that
bears ERa and to a lesser extent PR expression in hepa-
tocytes. Since most receptor conversion was seen in the
liver, and the fact that most biopsies from breast cancer
metastases are small and therefore probably quickly and
well fixed, it is unlikely that these issues play an impor-
tant role. A further limitation was the deliberate choice
not to include the preferential metastatic site of breast
cancer: the bone (marrow). This was to avoid false nega-
tive results due to decalcification artefacts. Such false
negative results are not easy to trace since internal posi-
tive control cells in the bone marrow are lacking. Future
studies selectively studying small bone biopsies that
were not decalcified may shed further light on percen-
tages of conversion on this metastatic site.
Nearly 11% of the patients converted from ER+ or PR
+ to ER-/PR- and 3.4% from ER-/PR- to ER+ or PR+
(using the 10% threshold); in these cases steroid recep-
tor conversion could be especially clinically relevant.
Together with the HER2 conversion rate of 5.2% by
IHC, in about 19% of metastatic patients the choice of
systemic therapy is suboptimal when solely based on
IHC of the primary tumor. However, before concluding
that metastases should be biopsied when possible, there
Table 4 Silver in situ hybridization results for breast cancer cases showing HER2 receptor conversion in distant
metastases by immunohistochemistry or 2+ scores by immunohistochemistry in either the primary tumor or the
metastasis
Case HER2 (IHC)
primary tumor
HER2 (SISH)
primary tumor
HER2 (IHC)
metastasis
HER2 (SISH)
metastasis
Metastatic site
1 0 No amplification 2+ No signal lung
2 0 No amplification 2+ No signal liver
3 0 High amplification 3+ High amplification liver
4 0 Low amplification 3+ Low amplification skin
5 1+ No amplification 2+ High amplification lung
6 1+ No amplification 2+ No amplification skin
7 1+ No amplification 3+ High amplification skin
8 1+ No amplification 3+ High amplification liver
9 2+ High amplification 2+ High amplification liver
10 2+ High amplification 2+ High amplification liver
11 2+ Low amplification 2+ Low amplification liver
12 2+ Low amplification 3+ High amplification liver
13 2+ Low amplification 3+ High amplification liver
14 3+ High amplification 0 No amplification liver
15 3+ High amplification 0 No amplification liver
16 3+ High amplification 0 No amplification gastro-intestinal
17 3+ High amplification 2+ High amplification brain
18 3+ High amplification 2+ No signal lung
19 3+ High amplification 2+ High amplification lung
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; SISH, silver in situ hybridization.
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are a few issues to consider. Clinicians would probably
be inclined to treat patients with positively converted
distant metastases (3.4 + 2.6 = 6%) with the matching
(hormonal or trastuzumab) systemic treatment, but for
patients with negatively converted distant metastases
this is probably more complicated. First, technical pro-
blems in cases with receptor negative metastases cannot
be fully excluded. Second, there may be heterogeneity
between distant metastases from which only one may
get biopsied [40]. Third, there are few clinical data on
response to systemic treatment in negatively converted
patients. Therefore, clinicians might be inclined to con-
sider (hormonal or trastuzumab) systemic treatment
even in negatively converted patients. Nevertheless,
when a biopsy of a distant metastasis is available, hor-
mone receptor and HER2 status should be reassessed in
these biopsies and the tests results should be critically
evaluated in conjunction with ER, PR and HER2 status
of the primary tumor. In the future, non-invasive assess-
ment of the receptor status by molecular imaging may
form an alternate and more functional way of assessing
receptor status of distant metastases [24-26], especially
for metastases at inaccessible sites, also providing infor-
mation on heterogeneity of receptor status between dis-
tant metastases.
Conclusions
In conclusion, receptor conversion in distant non-bone
breast cancer metastases indeed occurs, is relatively
uncommon for ERa and HER2, more frequent for PR,
and seems to be more frequent in liver and brain metas-
tases. In a considerable number of patients such conver-
sion could theoretically have consequences for the
systemic therapeutic regimen. For this reason, receptor
status should therefore be reassessed on available biop-
sies from distant metastases. Whether distant breast can-
cer metastases should be more routinely biopsied when
possible, will likely be the subject of further discussion.
In the future, non-invasive assessment of the receptor
status by molecular imaging may be an attractive alterna-
tive, especially for metastases that are difficult to biopsy.
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